Z. A. Ronai

RNF185 control of COL3A1 expression limits prostate cancer migration and metastatic potential.

This study shows RNF185 limits prostate cancer migration and metastasis by controlling COL3A1 expression.

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunity

This study identifies NR2F6 as a melanoma-intrinsic regulator of anti-tumor immunity, showing that its inhibition enhances immunotherapy response and tumor suppression.

Control of alveolar macrophage differentiation by Siah1a/2 ubiquitin ligases limits carcinogen-induced lung adenocarcinoma

This study shows that Siah1a/2 ubiquitin ligases regulate alveolar macrophage differentiation, and their loss promotes lung adenocarcinoma by increasing immature macrophages and pro-tumorigenic inflammation.

Melanoma Addiction to GCDH is Mediated by NRF2 Tumor Suppressor Function

This study identifies melanoma addiction to GCDH, showing that GCDH controls NRF2 glutarylation, which limits apoptotic UPR signaling and tumor growth.

RNF5 Regulation of RBBP4 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

This study shows RNF5 promotes AML growth by regulating RBBP4 and epigenetic pathways, and its inhibition enhances sensitivity to HDAC inhibitors, suggesting it as a therapeutic target and biomarker.

Tumor-educated monocyte-dendritic progenitors promote a metastatic switch

The paper shows that metastatic tumors drive HSPCs to differentiate into monocyte-dendritic progenitors via IL-6, promoting metastasis.

Regulation of HDAC2-PDX1 by RNF125 defines pancreatic cancer development

This study identifies RNF125's role in regulating HDAC2 and PDX1 to influence pancreatic cancer development and patient outcomes.

Integrated computational and experimental identification of p53, KRAS and VHL mutant selection associated with CRISPR-Cas9 editing

The paper identifies p53, KRAS, and VHL mutations as being selected during CRISPR-Cas9 editing through computational and experimental analysis.